RAFARMA PHARMA (WY) - RAFA STOCK NEWS

Rafarma Pharmaceuticals (OTC: RAFA) is collaborating with Krastsvetmet, a leading producer of precious metals in Russia, to develop a project focused on platinum-based chemotherapy drugs. This partnership aims for a production capacity of up to one ton annually. Experts predict a 6.3% increase in platinum use in the medical sector this year, driven by the rising prevalence of chronic diseases and an aging population. Although the collaboration requires significant capital investment, it is expected to yield substantial returns, aligning with market growth trends.

Rafarma Pharmaceuticals, Inc. (OTC: RAFA) provided a shareholder update on August 10, 2021, highlighting the ongoing audit process as they aim to file Form 10 with the SEC. The audit, which includes assets mainly located in Russia, is crucial for achieving SEC reporting status. Chairman Ilya Shpurov expressed confidence in completing the audit within 6-8 weeks, stating it involves consolidating reports from several large companies. The company has also signed agreements to develop new drugs for behavioral disorders, with further announcements expected soon.

Rafarma Pharmaceuticals (OTC: RAFA) received recognition for its Tashkent plant project from Uzbekistan's pharmaceutical development agency, marking it as the largest innovative project in the Tashkent Pharma Park. Planned for completion by the end of 2026, the project will include the production of cancer drugs and blood plasma-based medications. The $85 million investment will also establish GMP-standard laboratories for blood plasma collection. Work is set to commence this year, highlighting Rafarma's commitment to advancing pharmaceutical capabilities in the region.

Rafarma Pharmaceuticals (OTC: RAFA), a biopharmaceutical company, recorded approximately USD 75 million in gross revenue and USD 15 million in profit for 2020. The company focuses on developing innovative drugs, including radiopharmaceuticals, nanotechnology-based therapies, and sterile biological products. Rafarma is expanding its projects in Russia, Slovenia, Uzbekistan, and marketing in China and the Eurasian Economic Union. The company aims to establish a profitable drug portfolio in Eastern Europe and Central Asia.

Rafarma Pharmaceuticals (RAFA) has announced its active discussions with the City Scientific University of Istanbul to establish a nuclear medicine and proton therapy center. This initiative aims to enhance cancer treatment, as proton therapy can deliver precise doses to challenging tumors with fewer side effects compared to traditional therapies. The company aspires to lead the development of multiple proton therapy centers, supported by insights from Modern Nuclear Technologies LLC on the benefits of this advanced treatment option.

Rafarma Pharmaceuticals (OTC: RAFA) announced on April 26, 2021, the initiation of negotiations with Matam Technopark in Haifa, Israel. The collaboration aims to develop and adapt pharmaceutical technologies, focusing on Exosome research and the creation of modified bacteria for new drug designs. Chairman Ilya Spurov emphasized the company's commitment to engaging with global pharmaceutical partners to enhance its biotech market presence. The Matam Technopark is notable for housing major tech firms like Amazon and Microsoft, representing a significant opportunity for Rafarma's growth.

Rafarma Pharmaceuticals, Inc. (OTC: RAFA) announced new strategies for aggressive global growth in 2021/2022. The company aims to enhance the promotion of its technologies through partnerships with around 200 companies across various countries, including the USA, EU, and ASEAN regions. Established partnerships include several firms in China, Uzbekistan, and Russia. These collaborations are expected to expedite market access and reduce promotional costs, ultimately facilitating the development and distribution of new medicinal drugs and technologies.

Rafarma Pharmaceuticals, Inc. (OTC: RAFA) has announced a joint venture with the Pharmaceutical Industry Development Agency of Uzbekistan to produce medicines for public health institutions in Uzbekistan. The partnership involves acquiring 10 hectares in the Tashkent Pharma Park and constructing a facility, with projected costs of $82,000,000. The project is slated for completion between 2021 and 2025, with Rafarma providing expertise and equipment while the Agency handles registration and contracts.

Rafarma Pharmaceuticals, Inc. (OTC: RAFA) has successfully merged with BIOCOGENCY LABORATORIES, which will enhance its financial position by consolidating operations with Slavich and associated companies in Spain, Ireland, and Cyprus. The merger includes plans to divest Slovenian assets as per the agreement. CEO Vladimir Dolgolenko expressed excitement over this new chapter, while Chairman Ilya Spurov emphasized efforts to optimize assets and enhance market capitalization and stock liquidity through new products and sales channels.